High activity of daily-schedule mitoxantrone in newly diagnosed low-grade non-Hodgkin's lymphomas: a 5-year follow-up.
Twenty-one consecutive previously untreated patients with low-grade non-Hodgkin's lymphoma were entered into a trial of mitoxantrone (5 mg/m2 daily for 3 days repeated every 3 weeks) between 1985 and 1986. After 8 to 11 cycles of treatment not exceeding a cumulative dose of 165 mg/m2, the patients were observed without further treatment. Seven patients had small lymphocytic lymphomas, 10 had follicular small cleaved cell lymphomas, and 4 had follicular mixed small- and large-cell lymphomas. As previously reported, both hematologic and nonhematologic toxicity was modest. Nine patients achieved complete remission (CR) and 12 partial remission (PR) (CR plus PR = 100%). In the subsequent 4- to 5-year observation phase, 1 patient withdrew from the study, 10 patients relapsed, and 10 remain in unmaintained remission (7 CR, 3 stable PR). Three relapsed patients have died of treatment-resistant disease. No long-term side effects have been observed. Follow-up studies of left ventricular ejection fraction using multiple-gated acquisition scintigraphy showed no significant decrease in cardiac function.